Chaminda Sellahewa

Learn More
BACKGROUND Both obesity and over-expression of HER II are associated with poor prognosis of breast cancer. In vitro experiments suggest that anti-tumour activity of the anti-obesity drug Orlistat is likely to be due to transcriptional suppression of HER II expression. The overexpression of HER II is also positively correlated with other markers of prognosis(More)
BACKGROUND The risk of nodal metastasis is higher in women with bigger breast. It is not clear if this increase is due to the size of the breast (largely related to obesity) or is the result of larger tumour size at presentation (due to delayed diagnosis). It is hypothesised that women with large breasts are more likely to have node positive disease mainly(More)
  • 1